Morphic is working to develop a new generation of oral integrin drugs, focused on fibrosis, autoimmune disease and immuno-oncology.
Focused on oncology, eFFECTOR is developing a new class of small molecule therapies that act on protein targets that selectively regulate translational control of gene expression.
Alector is working on the discovery and development of first-in-class, disease-modifying, immuno-modulatory therapies for dementia and neurodegeneration.
Petra is developing small molecule inhibitors for the treatment of cancer and metabolic diseases.
Focused on multi-TA, Lodo is developing novel therapeutics derived from its metagenomics-based small molecule discovery platform.
Exicure is using novel nucleic acid-based technology to focus on immunomodulators and gene-silencing drugs against validated targets in inflammatory diseases and oncology.
Calimmune is working on gene therapy platforms for several diseases, including HIV infection.